左旋去甲麻黄碱结构式
|
常用名 | 左旋去甲麻黄碱 | 英文名 | (1S,2R)-(+)-Norephedrine |
---|---|---|---|---|
CAS号 | 37577-28-9 | 分子量 | 187.667 | |
密度 | 1.071g/cm3 | 沸点 | 288.1ºC at 760mmHg | |
分子式 | C9H13NO | 熔点 | 51-54ºC | |
MSDS | 美版 | 闪点 | 113 °C | |
符号 |
GHS07 |
信号词 | Warning |
中文名 | 左旋去甲麻黄碱 |
---|---|
英文名 | (1S,2R)-(+)-Norephedrine |
中文别名 | 苯基丙醇胺 | (1S,2R)-(+)-去甲麻黄碱 | D-(+)-苯丙醇胺 |
英文别名 | 更多 |
密度 | 1.071g/cm3 |
---|---|
沸点 | 288.1ºC at 760mmHg |
熔点 | 51-54ºC |
分子式 | C9H13NO |
分子量 | 187.667 |
精确质量 | 187.076385 |
PSA | 46.25000 |
LogP | 1.76750 |
计算化学 | 1、 疏水参数计算参考值(XlogP):0.8 2、 氢键供体数量:2 3、 氢键受体数量:2 4、 可旋转化学键数量:2 5、 拓扑分子极性表面积(TPSA):46.3 6、 重原子数量:11 7、 表面电荷:0 8、 复杂度:110 9、 同位素原子数量:0 10、 确定原子立构中心数量:2 11、 不确定原子立构中心数量:0 12、 确定化学键立构中心数量:0 13、 不确定化学键立构中心数量:0 14、 共价键单元数量:1 |
符号 |
GHS07 |
---|---|
信号词 | Warning |
危害声明 | H302-H315-H319-H335 |
警示性声明 | P261-P305 + P351 + P338 |
个人防护装备 | dust mask type N95 (US);Eyeshields;Gloves |
危害码 (欧洲) | Xn: Harmful; |
风险声明 (欧洲) | R22;R36/37/38 |
安全声明 (欧洲) | S26 |
危险品运输编码 | NONH for all modes of transport |
WGK德国 | 3 |
海关编码 | 2922199090 |
闪点(华氏) | 235.4 °F |
闪点(摄氏) | 113 °C |
左旋去甲麻黄碱上游产品 7 | |
---|---|
左旋去甲麻黄碱下游产品 7 | |
海关编码 | 2922199090 |
---|---|
中文概述 | 2922199090. 其他氨基醇及其醚,酯和它们的盐(但含一种以上含氧基的除外). 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:30.0% |
申报要素 | 品名, 成分含量, 用途, 乙醇胺及其盐应报明色度, 乙醇胺及其盐应报明包装 |
Summary | 2922199090. other amino-alcohols, other than those containing more than one kind of oxygen function, their ethers and esters; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
The Psychostimulant Khat (Catha edulis) Inhibits CYP2D6 Enzyme Activity in Humans.
J. Clin. Psychopharmacol. 35 , 694-9, (2015) The use of khat (Catha edulis) while on medication may alter treatment outcome. In particular, the influence of khat on the metabolic activities of drug-metabolizing enzymes is not known. We performed... |
|
Solvent-free melting techniques for the preparation of lipid-based solid oral formulations.
Pharm. Res. 32(5) , 1519-45, (2015) Lipid excipients are applied for numerous purposes such as taste masking, controlled release, improvement of swallowability and moisture protection. Several melting techniques have evolved in the last... |
|
The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation.
Pharmacoeconomics 33 , 749-63, (2015) Following withdrawals, failures, and significant litigation settlements, drug product launches in the anti-obesity category slowed despite a large and growing unmet need. Litigation concerns, a more r... |
EINECS 238-900-2 |
dl-phenylpropanolamine |
d-NOREPHEDRINE BASE |
(1R,2S)-2-Amino-1-phenyl-1-propanol hydrochloride (1:1) |
PHENYLPROPANOLAMINEBASE |
d-Phenylpropanolamine |
dl-NOREPHEDRINE BASE |
MFCD00064411 |
Benzenemethanol, α-[(1S)-1-aminoethyl]-, (αR)-, hydrochloride (1:1) |
dl-propadrine |